We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:

  • A company with a treatment of complex perianal fistula in patients with Crohn's disease, with orphan drug status, in a multinational Ph III clinical trial, available for licensing.
  • A company with novel monoclonal antibody targeting HGF, ready for Ph II, with excellent safety and indication of activity in gastric cancer, with dominant IP position, available for licensing.
  • An oral, Ph III, GI orphan drug opportunity, for the treatment of Familial Adenomatous Polyposis, with statistically significant positive Ph III data in a related indication, available for licensing in the US and ex EU/JP territories.
  • A medical device company with an approved, minimally invasive device for reconstructive and cosmetic cartilage surgery, available for sale/licensing.
Download our presentation
PDF

Get a digital copy of our PDF presentation

Download PDF